33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) (vol 6, pg 115, 2018)

被引：9

作者：

Berry, Sneha ^{[1
]}

Giraldo, Nicolas ^{[1
]}

Nguyen, Peter ^{[1
]}

Green, Benjamin ^{[1
]}

Xu, Haiying ^{[1
]}

Ogurtsova, Aleksandra ^{[1
]}

Soni, Abha ^{[1
]}

Succaria, Farah ^{[1
]}

Wang, Daphne ^{[1
]}

Roberts, Charles ^{[1
]}

Stein, Julie ^{[1
]}

Engle, Elizabeth ^{[1
]}

Pardoll, Drew ^{[1
]}

Anders, Robert ^{[1
]}

Cottrell, Tricia ^{[1
]}

Taube, Janis M. ^{[1
]}

Tran, Ben ^{[3
]}

Voskoboynik, Mark ^{[4
]}

Kuo, James ^{[5
]}

Bang, Yung-Lue ^{[6
]}

Chung, Hyun-Cheo ^{[7
]}

Ahn, Myung-Ju ^{[8
]}

Kim, Sang-We ^{[9
]}

Perera, Ayesh ^{[2
]}

Freeman, Daniel ^{[2
]}

Achour, Ikbel ^{[2
]}

Faggioni, Raffaella ^{[2
]}

Xiao, Feng ^{[2
]}

Ferte, Charles ^{[2
]}

Lemech, Charlotte ^{[5
]}

Meric-Bernstam, Funda ^{[10
,19
]}

Werner, Theresa ^{[11
]}

Hodi, Stephen ^{[12
]}

Messersmith, Wells ^{[13
]}

Lewis, Nancy ^{[14
]}

Talluto, Craig ^{[15
]}

Dostalek, Mirek ^{[14
]}

Tao, Aiyang ^{[14
]}

McWhirter, Sarah ^{[16
]}

Trujillo, Damian ^{[16
]}

Luke, Jason ^{[17
]}

Xu, Chunxiao ^{[18
]}

BoMarelli ^{[18
]}

Qi, Jin ^{[18
]}

Qin, Guozhong ^{[18
]}

Yu, Huakui ^{[18
]}

Jenkins, Molly ^{[18
]}

Lo, Kin-Ming ^{[18
]}

Halle, Joern-Peter ^{[18
]}

Lan, Yan ^{[18
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA

[2] MedImmune, Gaithersburg, MD 20878 USA

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Nucleus Network, Melbourne, Australia

[5] Sci Clin Res, Sydney, NSW, Australia

[6] Seoul Natl Univ Hosp, Seoul, South Korea

[7] Yonsei Univ, Yonsei Canc Ctr, Seoul, South Korea

[8] Samsung Med Ctr, Seoul, South Korea

[9] Asan Med Ctr, Seoul, South Korea

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Univ Utah, Salt Lake City, UT USA

[12] Dana Faber Canc Inst, Boston, MA USA

[13] Univ Colorado, Canc Ctr, Aurora, CO USA

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Inst BioMed Resea, Cambridge, MA USA

[16] Aduro Biotech Inc, Berkeley, CA USA

[17] Aduro Biotech Inc, Chicago, IL USA

[18] EMD Serono Res & Dev, Belmont, MA 01821 USA

[19] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[20] McKesson Specialty Hlth, Las Vegas, NV 89169 USA

[21] Eisai Inc, Woodcliff Lake, NJ USA

[22] Merck & Co Inc, Kenilworth, NJ USA

[23] South Texas Accelerated Res Therape, San Antonio, TX USA

[24] Abramson Canc Ctr Univ, Philadelphia, PA 19380 USA

[25] McKesson Specialty Hlth, Las Vegas, NV USA

[26] South Texas Accelerated Res Therape, San Antonio, TX USA

[27] Eisai Inc, Woodcliff Lake, NJ USA

[28] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[29] Ewha Womans Univ, Seoul, South Korea

[30] MD Healthcare Co, Seoul, South Korea

[31] Natl Univ Canc Inst, Singapore, Singapore

[32] Vall dHebron Inst Oncol, Barcelona, Spain

[33] Canc Inst Hosp JFCR, Tokyo, Japan

[34] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[35] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[36] Novartis Pharmaceut, E Hanover, NJ USA

[37] Novartis Inst BioMed Resea, Cambridge, MA USA

[38] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷

关键词：

IPILIMUMAB; PEMBROLIZUMAB; NIVOLUMAB;

D O I：

10.1186/s40425-019-0519-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.

引用

页数：11

共 26 条

[1] [Anonymous], 2018, IMF PRESCR INF
[2] [Anonymous], 2017, KEYTR PEMBR
[3] [Anonymous], 2018, YERV PRESCR INF
[4] [Anonymous], 2018, J. Immunother. Cancer, V6, P115, DOI [DOI 10.1186/S40425-018-0423-X, 10.1186/s40425-018-0423-x]
[5] Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Antonia, Scott
Goldberg, Sarah B.
Balmanoukian, Ani
Chaft, Jamie E.
Sanborn, Rachel E.
Gupta, Ashok
Narwal, Rajesh
Steele, Keith
Gu, Yu
Karakunnel, Joyson J.
Rizvi, Naiyer A.
[J]. LANCET ONCOLOGY, 2016, 17 (03) : 299 - 308
[6] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J.
de Wit, R.
Vaughn, D. J.
Fradet, Y.
Lee, J. -L.
Fong, L.
Vogelzang, N. J.
Climent, M. A.
Petrylak, D. P.
Choueiri, T. K.
Necchi, A.
Gerritsen, W.
Gurney, H.
Quinn, D. I.
Culine, S.
Sternberg, C. N.
Mai, Y.
Poehlein, C. H.
Perini, R. F.
Bajorin, D. F.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
[7] Benhaddi, 2018, J IMMUNO THERAPY S1, V6, DOI [10.1186/s40425-018-0422-y, DOI 10.1186/S40425-018-0422-Y]
[8] BERRY S, 2018, J IMMUNOTHER CANCER, V6, P115, DOI DOI 10.1186/S40425-018-0423-X
[9] BIERMAN HR, 1953, CANCER-AM CANCER SOC, V6, P591, DOI 10.1002/1097-0142(195305)6:3<591::AID-CNCR2820060317>3.0.CO
[10] 2-M

← 1 2 3 →